HGH 191AA research

The HGH 191AA evidence base cited here is 5 sources — 1 clinical, 3 review. Its strongest evidence is human — a clinical study, most recently 2022 ("Long-term Safety of Growth Hormone in Adults with Growth Hormone Deficie…"). Regulatory status: FDA-approved (various).

• Human growth hormone (somatropin) is a 191-amino-acid pituitary polypeptide. Recombinant HGH is bioidentical to the natural hormone and is FDA-approved — for childhood and adult growth-hormone deficiency, HIV-associated wasting, and several pediatric growth disorders.
• It works both directly (lipolysis, protein synthesis) and indirectly, by stimulating IGF-1 in the liver and tissues — IGF-1 carries much of the growth/anabolic effect.
• The '191AA' label distinguishes true recombinant somatropin from older/inferior 192-aa material; legitimate product is a ~22 kDa, bioidentical protein.

HGH (somatropin/somatotropin) is the body's primary growth hormone, made by the anterior pituitary, and recombinant HGH is the bioidentical pharmaceutical version. Unlike most compounds on this site, it's a long-established FDA-approved drug for defined deficiency states — but it's also widely used off-label for body composition and 'anti-aging', which is where the risk/benefit shifts.

It is prescription-only for its approved uses; off-label use carries legal and health risks. Everything below is research/clinical context, not medical guidance.

Somatropin is a single-chain, 191-amino-acid polypeptide (~22,124 Da) with two intrachain disulfide bridges (4 cysteines). The recombinant form is produced via E. coli DNA technology and is structurally identical to endogenous GH.

• Pediatric GH deficiency (idiopathic or organic), plus Turner, Prader-Willi, SGA, Noonan, SHOX deficiency, and chronic renal insufficiency
• Adult GH deficiency (childhood- or adult-onset, e.g. from pituitary tumor/surgery/radiation/trauma) — requires biochemical confirmation
• HIV-associated wasting / cachexia

• KIMS long-term safety (2022, observational, 15,809 adult-GHD patients, mean 5.3 yr): de novo cancer incidence comparable to the general population (SIR 0.92).
• Effects on morbidity (2014 systematic review of RCTs): positive effects on cardiovascular surrogate markers and bone metabolism.
• Adult GHD syndrome (2011): characterized the adult-deficiency syndrome — reduced exercise tolerance, low mood, central adiposity, hyperlipidemia, reduced bone density.

Somatropin is an FDA-approved prescription drug for its defined indications; non-medical use is illegal in the US and prohibited in sport (WADA). Research-grade/underground material is unregulated and frequently counterfeit.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.